Bluechiip is a global pioneer in advanced biosample tracking and cryogenic management technology. This competitive transaction results in Bluechiip now operating as part of a broader Cryonix platform, which is designed to lead the next generation of sample management, traceability, and life sciences storage and logistics.
The Cryonix Group (Cryonix), is focused on transforming biosample management, traceability, and life sciences storage through advanced technology and innovation. As such, this acquisition will bolster Cryonix’s business operations, through Bluechiip Group’s status as a global pioneer in advanced bio sample tracking and cryogenic management technology.
Mills Oakley advised on all aspects of the competitive transaction, including corporate, restructuring and intellectual property. As part of the transaction Cryonix acquired a large number of patents and trade marks registered globally, including in Australia, United States and various countries across Europe.
The Mills Oakley team was led by Corporate Advisory Partner Andrew Chan, Stuart Lewin, Partner (Restructuring), and Lisa Egan, Partner (IP), who were assisted by lawyers including Laura Chesney, Associate, Eden Tsiaples, Lawyer, and Georgie O’Leary, Lawyer.
Commenting on the transaction, Andrew Chan said:
“It was a pleasure working with Cryonix and Romanis Cant to achieve a fantastic result for all parties involved. We look forward to seeing the continued growth of Cryonix as it aims to unlock the full potential of this technology.”
Moray & Agnew acted as legal advisor to the Bluechiip Group and Romanis Cant were appointed as administrators.
Hamish Ferguson
Marketing Manager
T: +61 2 9121 9089
E: [email protected]